171 related articles for article (PubMed ID: 24619016)
1. Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial.
Razzaghdoust A; Mozdarani H; Mofid B
Strahlenther Onkol; 2014 Aug; 190(8):739-44. PubMed ID: 24619016
[TBL] [Abstract][Full Text] [Related]
2. Reduction in radiation-induced lymphocytopenia by famotidine in patients undergoing radiotherapy for prostate cancer.
Razzaghdoust A; Mozdarani H; Mofid B; Aghamiri SM; Heidari AH
Prostate; 2014 Jan; 74(1):41-7. PubMed ID: 24019126
[TBL] [Abstract][Full Text] [Related]
3. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
4. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
[TBL] [Abstract][Full Text] [Related]
5. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy.
Yeh J; Lehrich B; Tran C; Mesa A; Baghdassarian R; Yoshida J; Torrey R; Gazzaniga M; Weinberg A; Chalfin S; Ravera J; Tokita K
Brachytherapy; 2016; 15(3):283-287. PubMed ID: 26853354
[TBL] [Abstract][Full Text] [Related]
7. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study.
Sanguineti G; Franzone P; Marcenaro M; Foppiano F; Vitale V
Strahlenther Onkol; 2003 Jul; 179(7):464-70. PubMed ID: 12835883
[TBL] [Abstract][Full Text] [Related]
8. The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: a double-blind, randomized trial.
Kneebone A; Mameghan H; Bolin T; Berry M; Turner S; Kearsley J; Graham P; Fisher R; Delaney G
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):628-35. PubMed ID: 11597802
[TBL] [Abstract][Full Text] [Related]
9. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
[TBL] [Abstract][Full Text] [Related]
10. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
[TBL] [Abstract][Full Text] [Related]
11. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
[TBL] [Abstract][Full Text] [Related]
12. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
[TBL] [Abstract][Full Text] [Related]
13. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.
Mariados N; Sylvester J; Shah D; Karsh L; Hudes R; Beyer D; Kurtzman S; Bogart J; Hsi RA; Kos M; Ellis R; Logsdon M; Zimberg S; Forsythe K; Zhang H; Soffen E; Francke P; Mantz C; Rossi P; DeWeese T; Hamstra DA; Bosch W; Gay H; Michalski J
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):971-977. PubMed ID: 26054865
[TBL] [Abstract][Full Text] [Related]
14. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
[TBL] [Abstract][Full Text] [Related]
17. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.
Kupelian PA; Reddy CA; Klein EA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):988-93. PubMed ID: 11704322
[TBL] [Abstract][Full Text] [Related]
18. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group.
O'Brien PC; Franklin CI; Poulsen MG; Joseph DJ; Spry NS; Denham JW
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):442-9. PubMed ID: 12243820
[TBL] [Abstract][Full Text] [Related]
19. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.
Jahraus CD; Bettenhausen D; Malik U; Sellitti M; St Clair WH
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1483-7. PubMed ID: 16099600
[TBL] [Abstract][Full Text] [Related]
20. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.
Prada PJ; Fernández J; Martinez AA; de la Rúa A; Gonzalez JM; Fernandez JM; Juan G
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):95-102. PubMed ID: 17707267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
